Comparative evaluation of NeoPUTTY and mineral trioxide aggregate for full pulpotomy in mature permanent molars with irreversible pulpitis: a randomized clinical study
Biomaterial Investigations in Dentistry · 13.08.2026 · 13 · 664-673
DOI: 10.2340/biid.v13.46677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomaterial Investigations in Dentistry, online erschienen am 13.08.2026. Verfasst von Shiwani Chawla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric and Preventive Dentistry, Post Graduate Institute of Dental Sciences, Rohtak, Haryana, India. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To compare the clinical and radiographic outcomes of NeoPUTTY and mineral trioxide aggregate (MTA) as medicaments for full pulpotomy in mature permanent molars with irreversible pulpitis in children. Materials and Methods: Forty-six mature permanent molars from 46 children aged 9–14 years (one tooth per child) were randomly allocated to NeoPUTTY (n = 23) or MTA (n = 23) groups. Full pulpotomy was performed under rubber dam isolation followed by immediate composite restoration. Clinical and radiographic outcomes were evaluated at 1, 3, 6, and 12 months and at 6 and 12 months, respectively. Postoperative pain was assessed at 24 h using a visual analog scale (VAS). Hemostasis time was recorded intraoperatively. Per-protocol analysis was performed using an independent t-test, Mann–Whitney U test, Chi-square test, and Fisher’s exact test (p < 0.05). The trial was registered on ClinicalTrials.gov (NCT07702942).
Results
Forty-four teeth (22 per group) completed the final analysis; one participant from each group was lost to follow-up. Mean VAS scores decreased significantly within 24 h in both groups (p < 0.001), from 6.48 ± 1.73 to 0.91 ± 1.12 (NeoPUTTY) and from 6.17 ± 1.47 to 0.65 ± 0.78 (MTA), with no significant intergroup difference. Overall success at 12 months was 95.5% in both groups (21/22; 95% confidence interval [CI]: 77.2–99.9; p = 1.000). Intra- and inter-examiner radiographic agreement was almost perfect (κ = 0.87 and 0.83). Treatment outcome was not significantly associated with jaw location, sex, pain duration, hemostasis time, caries depth, or Wolters pulpitis grade.
Conclusion
Within the limitations of this study and 12-month follow-up, no statistically significant differences were detected between NeoPUTTY and MTA in postoperative pain reduction or clinical/radiographic success after full pulpotomy in mature permanent molars with irreversible pulpitis. Adequately powered non-inferiority or equivalence trials with longer follow-up are required to confirm these preliminary findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric and Preventive Dentistry, Post Graduate Institute of Dental Sciences, Rohtak, Haryana, India.
ORCID-Profile: Shiwani Chawla, Ruchi Singhal, Ritu Namdev, Chanchal Kumari, Khusboo Chhanna
Zitieren
APA
Chawla, S., Singhal, R., Namdev, R., Kumari, C., & Chhanna, K. (2026). Comparative evaluation of NeoPUTTY and mineral trioxide aggregate for full pulpotomy in mature permanent molars with irreversible pulpitis: a randomized clinical study. Biomaterial Investigations in Dentistry, 13, 664-673. https://doi.org/10.2340/biid.v13.46677
Vancouver
Chawla S, Singhal R, Namdev R, Kumari C, Chhanna K. Comparative evaluation of NeoPUTTY and mineral trioxide aggregate for full pulpotomy in mature permanent molars with irreversible pulpitis: a randomized clinical study. Biomaterial Investigations in Dentistry. 2026;13:664-673. doi:10.2340/biid.v13.46677
BibTeX
@article{Chawla2026,
author = {Chawla, Shiwani and Singhal, Ruchi and Namdev, Ritu and Kumari, Chanchal and Chhanna, Khusboo},
title = {Comparative evaluation of NeoPUTTY and mineral trioxide aggregate for full pulpotomy in mature permanent molars with irreversible pulpitis: a randomized clinical study},
journal = {Biomaterial Investigations in Dentistry},
year = {2026},
volume = {13},
pages = {664--673},
doi = {10.2340/biid.v13.46677}
}
EUVIMED